99 related articles for article (PubMed ID: 16711753)
1. A combination of molecular dynamics and docking calculations to explore the binding mode of ADS-J1, a polyanionic compound endowed with anti-HIV-1 activity.
Manetti F; Tintori C; Armand-Ugón M; Clotet-Codina I; Massa S; Ragno R; Esté JA; Botta M
J Chem Inf Model; 2006; 46(3):1344-51. PubMed ID: 16711753
[TBL] [Abstract][Full Text] [Related]
2. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.
Armand-Ugón M; Clotet-Codina I; Tintori C; Manetti F; Clotet B; Botta M; Esté JA
Virology; 2005 Dec; 343(1):141-9. PubMed ID: 16168454
[TBL] [Abstract][Full Text] [Related]
3. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.
González-Ortega E; Mena MP; Permanyer M; Ballana E; Clotet B; Esté JA
Antimicrob Agents Chemother; 2010 Oct; 54(10):4487-92. PubMed ID: 20643898
[TBL] [Abstract][Full Text] [Related]
4. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
Wang H; Qi Z; Guo A; Mao Q; Lu H; An X; Xia C; Li X; Debnath AK; Wu S; Liu S; Jiang S
Antimicrob Agents Chemother; 2009 Dec; 53(12):4987-98. PubMed ID: 19786602
[TBL] [Abstract][Full Text] [Related]
5. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
Hamza A; Zhan CG
J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
[TBL] [Abstract][Full Text] [Related]
6. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
7. A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120-CD4 protein-protein interactions.
Caporuscio F; Tafi A; González E; Manetti F; Esté JA; Botta M
Bioorg Med Chem Lett; 2009 Nov; 19(21):6087-91. PubMed ID: 19783140
[TBL] [Abstract][Full Text] [Related]
8. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.
Debnath AK; Radigan L; Jiang S
J Med Chem; 1999 Aug; 42(17):3203-9. PubMed ID: 10464007
[TBL] [Abstract][Full Text] [Related]
9. Specific CD4 down-modulating compounds with potent anti-HIV activity.
Vermeire K; Schols D
J Leukoc Biol; 2003 Nov; 74(5):667-75. PubMed ID: 12960237
[TBL] [Abstract][Full Text] [Related]
10. Targeting HIV entry through interaction with envelope glycoprotein 120 (gp120): synthesis and antiviral evaluation of 1,3,5-triazines with aromatic amino acids.
Lozano V; Aguado L; Hoorelbeke B; Renders M; Camarasa MJ; Schols D; Balzarini J; San-Félix A; Pérez-Pérez MJ
J Med Chem; 2011 Aug; 54(15):5335-48. PubMed ID: 21749165
[TBL] [Abstract][Full Text] [Related]
11. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
Teixeira C; Serradji N; Maurel F; Barbault F
Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
[TBL] [Abstract][Full Text] [Related]
12. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives.
Naicker KP; Jiang S; Lu H; Ni J; Boyer-Chatenet L; Wang LX; Debnath AK
Bioorg Med Chem; 2004 Mar; 12(5):1215-20. PubMed ID: 14980633
[TBL] [Abstract][Full Text] [Related]
14. The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes.
Sachdev DD; Zerhouni-Layachi B; Ortigoza M; Profy AT; Tuen M; Hioe CE; Klotman ME
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):125-9. PubMed ID: 19349871
[TBL] [Abstract][Full Text] [Related]
15. Multiple and multivalent interactions of novel anti-AIDS drug candidates, sulfated polymannuronate (SPMG)-derived oligosaccharides, with gp120 and their anti-HIV activities.
Liu H; Geng M; Xin X; Li F; Zhang Z; Li J; Ding J
Glycobiology; 2005 May; 15(5):501-10. PubMed ID: 15616125
[TBL] [Abstract][Full Text] [Related]
16. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
Neffe AT; Meyer B
Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309
[No Abstract] [Full Text] [Related]
17. Is the conformational flexibility of piperazine derivatives important to inhibit HIV-1 replication?
Teixeira C; Serradji N; Amroune S; Storck K; Rogez-Kreuz C; Clayette P; Barbault F; Maurel F
J Mol Graph Model; 2013 Jul; 44():91-103. PubMed ID: 23748247
[TBL] [Abstract][Full Text] [Related]
18. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
Andrianov AM; Kornoushenko YV; Kashyn IA; Kisel MA; Tuzikov AV
J Biomol Struct Dyn; 2015; 33(5):1051-66. PubMed ID: 24942968
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human immunodeficiency virus 1 replication in vitro by a self-stabilized oligonucleotide with 2'-O-methyl-guanosine-uridine quadruplex motifs.
Kuwasaki T; Hatta M; Takeuchi H; Takaku H
J Antimicrob Chemother; 2003 Apr; 51(4):813-9. PubMed ID: 12654739
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV entry by carbohydrate-binding proteins.
Balzarini J
Antiviral Res; 2006 Sep; 71(2-3):237-47. PubMed ID: 16569440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
